JACC. Case reports · 2026
Off-Label Use of Septal Occluder Devices for Recurrent Tricuspid Regurgitation Following TEER.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jaly Firas, Priebe-Brämer Holger, Dickmann Boris, Klajn Jadwiga, Hippe Hans-Jörg
Аннотация
BACKGROUND: Recurrent severe tricuspid regurgitation (TR) after transcatheter edge-to-edge repair (TEER) remains a therapeutic dilemma when redo clipping, surgery, or heterotopic caval valve implantation are not feasible.
CASE SUMMARY: We report 4 high-risk patients with massive to torrential TR due to interclip coaptation defects who were treated with off-label percutaneous closure using septal occluder devices. Procedural strategy evolved from transfemoral to right internal jugular access to improve coaxial alignment and deployment control. Early atrial septal occluders embolized, whereas muscular ventricular septal defect occluders, with a broader waist, provided stable anchoring and durable TR reduction. Balloon test occlusion and meticulous intraprocedural imaging were essential to avoid iatrogenic tricuspid stenosis. Clinical outcomes ranged from sustained symptomatic improvement to persistent right heart failure in advanced disease. Together, these cases suggest that in anatomically selected patients, occluder implantation may represent a feasible salvage strategy for recurrent TR after TEER when established therapies are not possible.
CASE SUMMARY: We report 4 high-risk patients with massive to torrential TR due to interclip coaptation defects who were treated with off-label percutaneous closure using septal occluder devices. Procedural strategy evolved from transfemoral to right internal jugular access to improve coaxial alignment and deployment control. Early atrial septal occluders embolized, whereas muscular ventricular septal defect occluders, with a broader waist, provided stable anchoring and durable TR reduction. Balloon test occlusion and meticulous intraprocedural imaging were essential to avoid iatrogenic tricuspid stenosis. Clinical outcomes ranged from sustained symptomatic improvement to persistent right heart failure in advanced disease. Together, these cases suggest that in anatomically selected patients, occluder implantation may represent a feasible salvage strategy for recurrent TR after TEER when established therapies are not possible.